-
Featured
The Role of Radiology in Identifying Intimate Partner Violence
Radiologists can play an important role in identifying cases of IPV and helping ensure patients receive the help they need, even when they are seeking care for unrelated reasons.
-
Editorial: Artificial Intelligence May Allow Reduced Use of Gadolinium-based Contrast Agents
Commenting on a German study, Manisha Bahl, MD, MPH, explains how AI can be applied to breast MRI scans acquired with low doses of gadolinium-based contrast agents (GBCAs) and predict the appearance of full-dose contrast-enhanced subtraction images, a potential way to reduce the dose and therefore toxicity of GBCAs.
-
Editorial: Time for Change in Digital Breast Tomosynthesis Research
Daniel B. Kopans, MD, of the Radiology Department at Mass General, says it's time to stop researching digital breast tomosynthesis using sequential cohorts. He suggests a simple, direct method to study whether replacing synthetic two-dimensional images with full-field digital mammographic images is warranted.
-
Editorial: Emerging Indications for Contrast-enhanced Mammography
Manisha Bahl, MD, MPH, a radiologist in the Breast Imaging Division in the Department of Radiology, explains the importance of a recent systematic review and meta-analysis that includes all literature published to date on contrast-enhanced mammography.
-
Magnetic Particle Imaging May Allow Intraoperative Breast Tumor Margin Assessment
Erica E. Mason, PhD, and Lawrence L. Wald, PhD, of the Martinos Center for Biomedical Imaging, and colleagues are exploring magnetic particle imaging as a fast way to assess margin status during breast-conserving surgery, with the aim of reducing the need for a second surgery.
-
PTEN Loss Mediates Cross-Resistance to CDK4/6 and PI3Ka Inhibitors in Breast Cancer
Dejan Juric, MD and colleagues have provided proof of concept that a single genetic event—in this study, loss of PTEN expression in estrogen receptor–positive, HER2-negative advanced breast cancer—can cause cross-resistance to multiple targeted therapies and affect subsequent lines of treatment.